• Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study.

OBJECTIVE: To assess baseline rates of and changes in HIV drug and sexual risk behavior as a function of gender and treatment in opioid-dependent youth. METHODS: One hundred fifty participants were randomly assigned to extended buprenorphine/naloxone therapy (BUP) for 12 weeks or detoxification for 2 weeks; all received drug counseling for 12 weeks. HIV risk was assessed at baseline and 4-week, 8-week, and 12-week follow-ups. Behavioral change was examined using generalized estimating equations. RESULTS: Baseline rates of past-month HIV risk for females/males were 51%/45% for injection drug use (IDU) (ns), 77%/35% for injection risk (P < 0.001), 82%/74% for sexual activity (ns), 14%/24% for multiple partners (ns), and 68%/65% for unprotected intercourse (ns). IDU decreased over time (P < 0.001), with greater decreases in BUP versus detoxification (P < 0.001) and females versus males in BUP (P < 0.05). Injection risk did not change for persistent injectors. Sexual activity decreased in both genders and conditions (P < 0.01), but sexual risk did not. CONCLUSIONS: Overall, IDU and sexual activity decreased markedly, particularly in BUP patients and females, but injection and sexual risk behaviors persisted. Although extended BUP seems to have favorable effects on HIV risk behavior in opioid-dependent youth, risk reduction counseling may be necessary to extend its benefits.

Pubmed ID: 20393347

Authors

  • Meade CS
  • Weiss RD
  • Fitzmaurice GM
  • Poole SA
  • Subramaniam GA
  • Patkar AA
  • Connery HS
  • Woody GE

Journal

Journal of acquired immune deficiency syndromes (1999)

Publication Data

September 24, 2010

Associated Grants

  • Agency: NIDA NIH HHS, Id: K05 DA017009
  • Agency: NIDA NIH HHS, Id: K05 DA017009-10
  • Agency: NIDA NIH HHS, Id: K05-DA017009
  • Agency: NIDA NIH HHS, Id: K12 DA000357
  • Agency: NIDA NIH HHS, Id: K12 DA000357-13
  • Agency: NIDA NIH HHS, Id: K12-DA000357
  • Agency: NIDA NIH HHS, Id: K24 DA022288
  • Agency: NIDA NIH HHS, Id: K24 DA022288-05
  • Agency: NIDA NIH HHS, Id: K24-DA022288
  • Agency: NIAID NIH HHS, Id: P30 AI064518
  • Agency: NIAID NIH HHS, Id: P30 AI064518-06
  • Agency: NIAID NIH HHS, Id: P30-AI064518
  • Agency: NIDA NIH HHS, Id: U10 DA013034
  • Agency: NIDA NIH HHS, Id: U10 DA013034-12
  • Agency: NIDA NIH HHS, Id: U10 DA013043
  • Agency: NIDA NIH HHS, Id: U10 DA013043-12
  • Agency: NIDA NIH HHS, Id: U10 DA013711-04
  • Agency: NIDA NIH HHS, Id: U10 DA015831
  • Agency: NIDA NIH HHS, Id: U10 DA015831-10
  • Agency: NIDA NIH HHS, Id: U10 DA015833-03
  • Agency: PHS HHS, Id: U10-013034
  • Agency: NIDA NIH HHS, Id: U10-DA013043
  • Agency: NIDA NIH HHS, Id: U10-DA013711
  • Agency: NIDA NIH HHS, Id: U10-DA015831
  • Agency: NIDA NIH HHS, Id: U10-DA015833

Mesh Terms

  • Adolescent
  • Analgesics, Opioid
  • Buprenorphine
  • Female
  • HIV Infections
  • Humans
  • Male
  • Naloxone
  • Narcotic Antagonists
  • Patient Acceptance of Health Care
  • Risk Assessment
  • Risk-Taking
  • Sexual Behavior
  • Substance Abuse, Intravenous
  • Substance-Related Disorders
  • Young Adult